Market Research Future (MRFR) announces the launch of a new release on the global hemiplegic migraine market. The report projects the global hemiplegic migraine market to show a CAGR of 3.3% from 2018 to 2023, growing to a value of USD 1,008 mn by 2023. The market was valued at USD 830 million in 2017.

Hemiplegic migraines market growth are a rare form of migraine and occur in two patterns. One is called familial hemiplegic migraine, which is a hereditary condition that affects at least two close relatives in a family, whereas the other is known as sporadic hemiplegic migraine, as it can occur anywhere. The growing prevalence of sound pollution, air pollution, and growing stress in workplaces have driven the prevalence of hemiplegic migraines over the last few years. As a result, the prevalence of sporadic hemiplegic migraine is much higher than that of familial hemiplegic migraine. Lifestyle factors are likely to take on an ever more important role in the global hemiplegic migraine market’s growth over the forecast period, as hemiplegic migraines are often brought on by environmental factors.

Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/6713

Growing awareness about migraines and the increasing ease of obtaining migraine medication are likely to be the major drivers for the hemiplegic migraine market over the forecast period. Growing efforts by public healthcare agencies to raise awareness about migraines and the increasing disposable income of consumers around the world have resulted in increased prospects for the global hemiplegic migraine market over the forecast period.

Competitive Analysis:

Leading players in the global hemiplegic migraine market include Abbott Laboratories, AstraZeneca PLC, Endo International PLC, Impax Laboratories, Johnson & Johnson, Merck & Co., Eli Lilly and Company, GlaxoSmithKline PLC, Eisai Co. Ltd., and Allergan PLC.

Segmentation:

The global hemiplegic migraine market has been segmented on the basis of type, treatment, preventive treatment, distribution channel, end user, and region.

By Type, the market is segmented into familial hemiplegic migraine and sporadic hemiplegic migraine.
By End user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
By Treatment, the market is segmented into acute treatment, triptans, ergotamines, NSAIDs, antiemetics, narcotic analgesics, and others.
By Preventive Treatment, the market is segmented into antidepressants, botox injections, and others.
By Distribution Channel, the market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others.
Regional Analysis:

The global hemiplegic migraine is segmented into the Americas, the Middle East and Africa, Asia Pacific, and Europe. The Americas is likely to be the major regional segment in the global hemiplegic migraine market over the forecast period due to the presence of a large consumer pool and the increasing development of effective treatments for hemiplegic migraine. The strong medical research sector in the U.S. and Canada is likely to be a major driver for the hemiplegic migraine market over the forecast period, along with the increasing disposable income of consumers in emerging Latin American countries such as Mexico, Brazil, Chile, and Argentina.

Europe also holds a leading position in the global hemiplegic migraine market and is likely to hold on to the position over the forecast period due to the widespread awareness about the disease and the increasingly easy availability of hemiplegic migraine medication in Eastern European countries such as the Czech Republic, Austria, Poland, and Slovakia. Western European countries such as the UK, France, Germany, and Spain are mature markets for the healthcare sector and are likely to play a leading role in the market’s development over the forecast period.

Get Access Full Report @ https://www.marketresearchfuture.com/reports/hemiplegic-migraine-market-6713

Asia Pacific is likely to grow at a rapid growth rate over the forecast period due to the growing potential of the healthcare sector in developing Asia Pacific economies such as China, India, Indonesia, Malaysia, and Singapore. The growing spending capacity of the local consumers is likely to be a key driver for the hemiplegic migraine market in the region over the forecast period, as the region is home to several underdeveloped countries where a majority of the population may not be able to afford hemiplegic migraine medication on a regular basis.

Industry Updates:

A new case study found in January 2019 that cystic fibrosis may be a risk factor in causing hemiplegic migraine attacks.